10x Genomics Expands Leadership in Single Cell Analysis with Launch of GEM-X Technology

10x Genomics Expands Leadership in Single Cell Analysis with Launch of GEM-X Technology

GEM-X, the next generation of the company’s leading single cell technology architecture, enables higher performance at larger scale and lower cost

Pre-orders now open for first two Chromium products powered by GEM-X; expected to ship in Q1

PLEASANTON, Calif., Feb. 7, 2024 /PRNewswire/ — 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the launch of GEM-X, the next generation of the company’s leading single cell technology. The first major overhaul to the Chromium architecture since the 2019 launch of Next GEM technology, GEM-X is built on a new and improved microfluidic chip design, featuring the latest technological advancements and optimized reagents for superior performance and high reliability.

“With GEM-X, we are advancing our leadership in single cell analysis, raising the bar on performance and setting a new standard for the field,” said Michael Schnall-Levin, Founding Scientist and Chief Technology Officer of 10x Genomics. “This is a game-changing technology that will help drive better, faster and more cost effective single cell research and enable more academic and translational researchers to routinely rely on these tools to help resolve biology’s complexity.”

The company is now accepting preorders for the first two product launches powered by the GEM-X technology architecture, Chromium Single Cell Gene Expression 3’v4 and Chromium Single Cell Immune Profiling 5’v3. These assays are expected to begin shipping this quarter.

The new GEM-X technology offers significant performance advantages, including:

  • Substantially increased sensitivity: Detect up to two times more genes compared to on-market Chromium assays to gain a more comprehensive view of cellular heterogeneity
  • Built to scale: Two-fold increase in cells captured per channel
  • More cost effective: More than two-fold reduction in cost per cell
  • Enhanced data quality: Two-fold reduction in multiplet rate enabling high quality data at scale
  • Maximum sample recovery: Recovery of up to 80% of cells, improving capture efficiency and making it ideal for samples typically yielding few cells, such as tissue biopsies or previously flow sorted cells
  • Improved assay robustness: Redesigned microfluidics and optimized reagents for faster and more efficient cell partitioning

“This is just the beginning for GEM-X and for single cell analysis,” added Schnall-Levin. “We have a robust GEM-X roadmap ahead, including a comprehensive menu of high performance assays and applications with the economics to drive broad adoption and large scale.”

GEM-X is exclusively available for use on Chromium X Series instruments.

About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world’s understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn or X (Twitter).

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which fall under the “safe harbor” provisions of those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics, Inc.’s (“10x Genomics”) product launches, performance, configuration, costs, capabilities, adoption and pipeline. These statements are based on management’s current expectations, forecasts, beliefs, assumptions and information currently available to management, and actual outcomes and results could differ materially from these statements due to a number of factors. Other risks and uncertainties that could affect 10x Genomics’ financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents 10x Genomics files with the Securities and Exchange Commission (the “SEC”) from time to time. Although 10x Genomics believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or occur. The forward-looking statements in this press release are based on information available to 10x Genomics as of the date hereof, and 10x Genomics disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing 10x Genomics’ views as of any date subsequent to the date of this press release.

Disclosure Information
10x Genomics uses filings with the Securities and Exchange Commission, our website (www.10xgenomics.com), press releases, public conference calls, public webcasts and our social media accounts as means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD.

Contacts
Investors: [email protected]
Media: [email protected]

SOURCE 10x Genomics, Inc

Comments

No comments yet. Why don’t you start the discussion?

Leave a Reply

Your email address will not be published. Required fields are marked *